Patents by Inventor James Michael Pierce
James Michael Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9329169Abstract: The present invention relates to a method of isotopically labeling glycans and in facilitating high throughput quantitative/comparative analysis of glycomic compositions of biological cells. The method is applicable inter alia for identifying differentiated cells and their glycomic characteristics, differentiation conditions, disease and/or therapeutic progression, diagnosing disease states, determining drug activity, establishing manufacturing efficiencies and for determining the half-life of glycans in cells.Type: GrantFiled: October 29, 2008Date of Patent: May 3, 2016Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INCInventors: Robert Lance Wells, Ronald C. Orlando, Stephen Dalton, Kelley W. Moremen, James Michael Pierce, James A. Atwood, III, Michael Tiemeyer, William S. York
-
Publication number: 20140315212Abstract: The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (GPI-APs) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate GPI-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer. The method uses the alpha-toxin from Clostridium septicum to separate GPI-anchored glycoproteins for identification and optionally quantification. The GPI-APs so obtained may be used to raise antibodies for inclusion in an immunosorbent assay for the diagnosis or the monitoring of therapy of cancer in a patient.Type: ApplicationFiled: January 28, 2014Publication date: October 23, 2014Applicant: University of Georgia Research Foundation, Inc.Inventors: James Michael Pierce, Karen Lynn Abbott
-
Publication number: 20140154710Abstract: The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: James Michael Pierce, Karen L. Abbott
-
Patent number: 8623611Abstract: The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics.Type: GrantFiled: June 11, 2010Date of Patent: January 7, 2014Assignee: University of Georgia Research Foundation, Inc.Inventors: James Michael Pierce, Karen L. Abbott
-
Publication number: 20110033875Abstract: The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics.Type: ApplicationFiled: June 11, 2010Publication date: February 10, 2011Applicant: University of Georgia Research Foundation, Inc.Inventors: James Michael Pierce, Karen L. Abbott
-
Patent number: 7670815Abstract: A previously unknown mammalian UDP-N-acetylglucosamine:?-6-D-mannoside ?-1,6-N-acetylglucosaminyl-transferase (termed GlcNAc T-Vb herein) coding sequence, protein, recombinant host cells and antibodies which specifically bind GlcNAc T-Vb are described. In particular, GlcNAc T-Vb of mouse is disclosed.Type: GrantFiled: March 24, 2008Date of Patent: March 2, 2010Assignee: University of Georgia Research FoundationInventors: James Michael Pierce, Maria Kamar, Jin-Kyu Lee, Mika Kaneko
-
Patent number: 6015701Abstract: The present invention provides substantially purified UDP-N-acetylglucosamine: .alpha.-6-D-mannoside .beta.-1,6-N-acetylglucosaminyl transferase (GlcNAc T-V; EC 2.4.1.155) proteins and antibodies which specifically bind GlcNAc T-V. The present invention also provides polynucleotide sequences and oligonucleotide probes capable of specifically hybridizing to nucleic acid sequences which encode GlcNAc T-V, and cDNA and genomic clones encoding GlcNAc T-V, as well as nucleotide sequences encoding GlcNAc T-V, as specifically exemplified by GlcNAc T-V coding sequences from rat, hamster, mouse and human.Type: GrantFiled: July 19, 1994Date of Patent: January 18, 2000Assignees: University of Georgia Research Foundation, Inc., Amgen, Inc.Inventors: James Michael Pierce, Mohamed G. Shoreibah, Beverly Adler, Nevis Lee Fregien
-
Patent number: 5891698Abstract: The invention relates to humanized milk. The milk is produced by a non-human transgenic mammal wherein the genome of said transgenic non-human mammal contains at least one heterologous gene encoding for a human catalytic entity and wherein the catalytic entity produces oligosaccharides and glycoconjugates that are present in the milk of said transgenic non-human mammal. An especially useful catalytic entity is human glycosyltransferases which produce oligosaccharides and glyconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. A method of obtaining humanized milk is disclosed.Type: GrantFiled: May 2, 1995Date of Patent: April 6, 1999Assignee: Abbott LaboratoriesInventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
-
Patent number: 5892070Abstract: The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.Type: GrantFiled: September 10, 1996Date of Patent: April 6, 1999Assignee: Abbott LaboratoriesInventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
-
Patent number: 5750176Abstract: The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.Type: GrantFiled: March 9, 1994Date of Patent: May 12, 1998Assignee: Abbott LaboratoriesInventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
-
Patent number: 5700671Abstract: The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates.Type: GrantFiled: May 2, 1995Date of Patent: December 23, 1997Assignee: Abbott LaboratoriesInventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce